RxDoctor Payments DataLook up a doctor →

Ramesh Grandhi, MD

Neurological Surgery · Salt Lake City, UTNPI 1316179195

Payments from drug & device makers

$1,757,095in general payments, 2019–2025

Across 938 payments — averaging $1873.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$822K
  • Medical Device Business Services, Inc.$420K
  • Balt USA, LLC$224K
  • Biogen$79K
  • Route 92 Medical, Inc.$70K
  • Abbott$49K
  • plus $94K from 22 others
$2,415in research payments, 2019–2025

Across 4 payments — averaging $603.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$2K

What the payments were for

  • Consulting fees$247,19242%
  • Speaking & faculty fees$217,57137%
  • Travel & lodging$84,60814%
  • Food & beverage$33,3986%
  • Education$3,6001%
  • Gifts$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,757,095 in reported general payments places this provider in the 95th percentile of 75 neurological surgery providers in Utah.

See all neurological surgery providers in Utah

Medicare billing

Part B allowed, 2024
$141,971
Medicare patients
165
Services billed
764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate19$203
Atorvastatin Calcium21$124

Paid to pharmacies, not to this prescriber.

Other neurological surgery in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →